Correlation between therapy modalities and survival of lung cancer patients in Surabaya, Indonesia
DOI:
https://doi.org/10.30574/gscbps.2022.18.1.0022Keywords:
Lung cancer, Chemotherapy, Targeted therapy, SurvivalAbstract
Lung cancer is one of the leading causes of death worldwide. Lung cancer treatment are including surgery, chemotherapy, targeted therapy and radiotherapy. Despite therapy modalities mentioned above, lung cancer survival is remained poor. In this research we want to find out the correlation between the current treatment modalities used and the survival of lung cancer patients. Data source is secondary data collected from electronic medical records in oncology polyclinic of Dr. Soetomo General Academic Hospital. Data will be analyzed regarding the correlation between the therapy given and survival of the patients also the correlation between histologic types of lung cancer and therapy given using contingency coefficient. Coefficient we found weak correlation between cancer type and therapy modalities given (p<0.01 and C=0.301) where targeted therapy is related with adenocarcinoma. Moderate correlation between therapy given and survival of the patients (p<0.01, C=0.533). Targeted therapy related with better survival outcome compared to chemotherapy and patient that get only supportive care. Targeted therapy is related with better prognosis compared to chemotherapy and supportive care. Targeted therapy drugs that used in Adenocarcinoma found in this research is mainly targeting EGFR mutation. Squamous cell carcinoma and small-cell carcinoma mainly treated using platinum-based chemotherapy.
Metrics
References
Siddiqui F, Siddiqui AH. Lung Cancer. Cambridge Handb Psychol Heal Med Second Ed. 2021; 605–6.
Cruz CSD, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011; 32: 605–44.
Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016; 5: 288.
Raman V, Yang CFJ, Deng JZ, D’Amico TA. Surgical treatment for early stage non-small cell lung cancer. J Thorac Dis. 2018; 10: S898–904.
National Health Service [Internet]. Lung Cancer – Treatment. UK: NHS. 2019.
Lwin Z, Riess JW, Gandara D. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis. 2013; 5.
Ohmori T, Yamaoka T, Ando K, Kusumoto S, Kishino Y, Manabe R, et al. Molecular and clinical features of egfr-tki-associated lung injury. Int J Mol Sci. 2021; 22: 1–18.
Walach H. Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C, Matthes H: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One 2018;13:e0203058. Complement Med Res. 2018; 25: 372–4.
Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-Small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015; 5: 2892–911.
Mayekar MK, Bivona TG. Current landscape of targeted therapy in lung cancer. Clin Pharmacol Ther. 2017; 102: 757–64.
Chan BA, Coward JIG. Chemotherapy advances in small-cell lung cancer. J Thorac Dis. 2013; 5.
Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res. 2015; 4: 36–54.
Mok TS, Wu Y, Thongprasert S, Yang C, Saijo N, Sunpaweravong P, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947–57.
Aggarwal C. Targeted therapy for lung cancer: present and future. Ann Palliat Med. 2014; 3: 229–22935.
Lackey A, Donington J. Surgical management of lung cancer. Semin Intervent Radiol. 2013; 30: 133–40.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
